A pair of isogenic colon carcinoma cells, SW480 and 620, was used to investigate the mechanisms of acquired tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistance during tumour progression. Whereas primary tumour SW480 cells are sensitive to TRAILinduced apoptosis, metastatic SW620 cells are resistant. The apoptotic signalling activated by TRAIL in SW480 cells is a type II pathway. We show that in SW620 cells, although caspase-8 is recruited and activated at the deathinducing-signalling complex and Bid is cleaved, this does not lead to caspase-9 activation. Comparison of Bcl-2, Bcl-xL and Mcl-1 levels in both cell lines showed no difference. In SW620 cells transfected with a tBid-GFP construct, tBid-GFP was correctly localized to the mitochondria. Thus, the resistance of SW620 cells is at the level of the mitochondria that can withstand large amounts of tBid. Although caspase-3 was directly cleaved by caspase-8 in SW620 cells to yield the p20 fragment, no further autocatalytic maturation into the p17 fragment was observed. We show that, in contrast to SW480 cells, the SW620 cell line expresses high amounts of X-linked inhibitor of apoptosis (XIAP). Downregulation of XIAP with bortezomib or small-interfering RNA was sufficient to restore the sensitivity of SW620 cells to TRAILinduced apoptosis in the absence of SMAC/Diablo or cytochrome c release from the mitochondria. Thus, SW620 cells have developed a dual resistance to TRAIL-induced apoptosis: a block at the level of the mitochondria and, after a conversion to a type I pathway, an increased expression of XIAP which inhibits this pathway.
Introduction
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in numerous tumour cell lines and constitutive expression of TRAIL receptors has been observed in a variety of human tumour types. TRAIL does not exert any overt general toxicity and therapeutic agents that engage the TRAIL pathway are tested in clinical phase I/II studies alone or in combination with chemotherapeutic drugs (Koschny et al., 2007b) . However, inherent tumour resistance may be a major barrier to TRAIL-targeted therapy and the underlying mechanisms need to be understood to find ways to reverse this resistance.
Two cell death-inducing receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5) and two non-cell-death-inducing receptors (TRAIL-R3/DcR1 and TRAIL-R4/DcR2) have been identified for TRAIL, the latter two acting as decoys (Sheridan et al., 1997) . Upon TRAIL binding, DR4 and 5 are oligomerized leading to the recruitment of the adaptor molecule Fas-associated death domain. Subsequently, pro-caspase-8 is recruited and activated at the TRAIL death-inducing-signalling complex (DISC) (Kischkel et al., 2000) . Activated caspase-8 then either directly activates the effector caspase-3 (type I pathway) or, through Bid cleavage, triggers mitochondrial outer membrane permeabilization and caspase-9 activation (type II pathway; Ashkenazi, 2002) . The type I pathway is regulated at the level of caspase-3 activation by inhibitor-of-apoptosis proteins (IAPs) and the type II pathway is regulated at the level of mitochondria by members of the Bcl-2 family.
A physiological role for TRAIL in suppressing tumour metastasis has been demonstrated in several studies Takeda et al., 2001; Cretney et al., 2002; Grosse-Wilde et al., 2008) . Therefore, in some cases, metastasis formation may require acquisition of TRAIL-resistance during the last stages of tumour progression. In this study, we used a pair of isogenic colorectal carcinoma cells, SW480 and 620, to investigate the specific modifications responsible for the observed differences in TRAIL sensitivity between cells with low (SW480) or high (SW620) metastatic potential. These two cell lines have been validated as an in vitro model of colon cancer progression from a primary tumour to metastatic disease and have retained relevant phenotypes despite long-term culture in vitro (Hewitt et al., 2000) . The SW480 cell line was derived from a primary Duke's stage B colon carcinoma from a 50-year-old male patient. The SW620 cell line was derived from a mesenteric lymph node metastasis in the same patient 6 months later (Leibovitz et al., 1976) . A common monoclonal origin for both cell lines was confirmed by the presence of shared marker chromosomes revealed by cytogenetic analysis (Gagos et al., 1995) . Moreover, observed differences between the two cell lines in their sensitivity to apoptosis cannot be attributed to drug-induced selection as chemotherapy was not started until after the laparotomy for recurrent cancer (Hewitt et al., 2000) . SW480 cells have conserved an epithelial morphology whereas SW620 cells are less cohesive and have a rounded or fibroblast-like morphology reminiscent of cells having undergone the epithelial-mesenchymal transition (Hewitt et al., 2000) .
In this work, we show that acquisition of resistance to TRAIL-induced apoptosis in the metastatic cells compared to cells of the primary tumour occurred at two different levels: a mitochondrial block preventing mitochondrial outer membrane permeabilization and a cytosolic block inhibiting caspase-3 maturation.
Results

TRAIL-resistance in SW620 cells is downstream of Bid cleavage
The level of apoptosis, measured as the percentage of hypodiploid cells, was compared in a time course of SW480 and 620 cells treated with 25 ng/ml of recombinant TRAIL. As shown in Figure 1a , whereas almost 60% of SW480 cells were apoptotic after 24 h of culture, SW620 cells were totally resistant. No significant difference was found in the amount of DR4 or 5 between the two cell lines and neither DcR1 nor 2 were expressed ( Figure 1b) . In addition, FLICE-inhibitory protein (FLIP) splice variants (Krueger et al., 2001) were not detected in either SW480 or 620 cells (data not shown). Analysis of caspase activation indicated that the cleaved, mature forms of caspase-8 (p43/41), caspase-9 (p35) and caspase-3 (p17) were generated in SW480 cells (Figure 1c) . However, neither caspase-8 nor -9 appeared to be cleaved in SW620 cells and only the partially processed form, p20, of caspase-3 was detected. This fragment corresponds to caspase-3 cleaved by -8 between the large and the small subunit without the subsequent autocatalytic processing between the prodomain and the large subunit that generates the fully mature p17 form (Sun et al., 2002) . This indicated that caspase-8 was activated in SW620 cells but probably at too low a level to be detected by western blot. Therefore, we immunoprecipitated the DISC in both cell lines subjected to TRAIL to achieve an enrichment in DISC components. As shown in Figure 1d , caspase-8 was recruited and cleaved in the DISC of SW480 cells but also in that of SW620 cells indicating that the initiation of the signalling pathway was equally efficient in these cells. Caspase-8 activation was further supported by the observation that Bid, a caspase-8 substrate, was cleaved not only in SW480 but also in SW620 during TRAIL treatment as indicated by the decreased intensity of the native p22 form as early as 6 h after TRAIL addition (Figure 1e ). Together, these results indicate that TRAIL-resistance in SW620 cells occurs downstream of Bid cleavage.
TRAIL has been shown to lead to increased proliferation in some cell types, an effect which is abrogated by pharmacological inhibitors of the Erk pathway (Secchiero et al., 2004) . We therefore tested whether TRAIL could trigger proliferative instead of apoptotic signalling in SW620 cells. Time course studies showed that the presence of TRAIL did not modify the basal proliferation of these cells (Supplementary data 1A). Moreover, TRAIL induced a transient and comparable activation of Erk in SW480 and 620 cells indicating that this pathway is not likely to be involved in the different response to TRAIL of the two cell lines (Supplementary data 1B).
TRAIL-resistance in SW620 cells is not due to altered expression of Bcl-2 family members Antiapoptotic members of the Bcl-2 family are known to be important in inhibiting death-receptor-induced apoptosis in type II cells at the level of mitochondria (Gross et al., 1999) . We therefore investigated whether SW480 could be characterized as type I or II by generating stable clones of SW480 cells overexpressing the Bcl-2 protein. As shown in Figure 2a , the two SW480 clones expressing Bcl-2 at a high level (clones 4 and 14) were resistant to TRAIL-induced apoptosis (Figure 2a ), indicating that SW480 cells were type II cells. Upon stimulation with TRAIL, and as analysed by western blot, caspase-8, -9 or -3 cleavage was not detected in these clones (not shown). We then monitored the level of expression of the antiapoptotic proteins Bcl-2, Bcl-xL and Mcl-1 in SW620 cells compared to SW480 cells (Figure 2b ). The levels of Mcl-1, Bcl-2 and -xL were identical in both cell lines and unchanged by exposure to TRAIL. In SW480 cells, Mcl-1 was cleaved to generate a 24 kDa fragment as previously described (Menoret et al., 2006) . Therefore, the resistance of SW620 cells to TRAIL-induced apoptosis cannot be explained by increased levels of antiapoptotic Bcl-2 family proteins. As shown in Figure 2c , equal amounts of Bax and Bak are expressed in SW620 cells compared to SW480 cells thus ruling out the possibility that a Bax or Bak deficiency may cause TRAIL resistance in SW620 cells. We then explored the activation of Bax and Bak during TRAIL treatment in both cell lines with the use of antibodies specifically detecting their active forms. Whereas both Bax and Bak were activated in SW480 cells, this was not the case in SW620 cells (Figure 2d ). Thus, SW620 cells appear unable to activate Bax or Bak despite the presence of cleaved Bid (tBid).
TRAIL-resistance in SW620 cells is due to their insensitivity to mitochondrial tBid tBid-mediated Bax activation involves relocalization to the mitochondria where tBid can promote the insertion of Bax into the outer mitochondrial membrane (Letai et al., 2002) . To test whether there was a defect in tBid relocalization in SW620 cells, we tried to generate stable clones of SW480 and 620 cells expressing tBid coupled to GFP. Stable SW480 clones were not produced probably because tBid induces apoptosis in these cells. In contrast, more than 20 clones were obtained for SW620. Two of these clones are shown in Figure 3A . Simultaneous labelling with Mitotracker red indicated that the transfected tBid-GFP was indeed localized at the mitochondria. Thus, despite the presence of tBid in the mitochondria, SW620 clones do not die. We then tested whether there could be an inherent inability to activate Bax in these clones due to clonal selection. To this end, we investigated their sensitivity to TRAIL and staurosporine-induced apoptosis. As shown in Figure 3B , the clones are still resistant to TRAIL as is the case for the parental cell line. However, they are sensitive to staurosporine-induced cell death and Bax is activated and relocalized ( Figure 3C ), indicating that these clones have not acquired an intrinsic inability to activate Bax during the selection procedure.
To further investigate the relative sensitivity of SW480 and 620 cells to BH3 molecules, we used the BH3-mimetic ABT-737 that has been shown to neutralize Bcl-2, Bcl-xL and Bcl-w (Oltersdorf et al., 2005) . treatment assessed by western blot analysis using appropriate antibodies. Caspase-8:p55/53, proform, P43/41, cleavage fragments, *nonspecific band. Caspase-9: p47, proform; p37, cleavage fragment. Caspase-3: p32, proform; p20, p19, p17, cleavage fragments. (d) TRAIL receptors were immunoprecipitated using Flag-tagged recombinant TRAIL and anti-Flag M2 antibody at various times during TRAIL treatment. Coimmunoprecipitated DR5 (doublet at 49 and 43 kDa), Fas-associated death domain (FADD) and caspase-8 (proform and cleavage fragments) were revealed on western blots with appropriate antibodies. (e) Cleavage of Bid during TRAIL treatment was assessed by western blot by detection of reduced intensity of the 22 kDa band corresponding to full-length Bid (FLBid). Hsc70 was used as a loading control.
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As shown in Figure 3D , exposure to ABT-737 was sufficient to kill SW480 cells and its presence increased the sensitivity of these cells to TRAIL-induced apoptosis. In contrast, ABT-737 does not induce apoptosis in SW620 cells nor does it sensitize these cells to TRAIL. Taken together, these results indicate that SW620 cells display an inherent resistance to at least some BH3 or BH3-like molecules.
Bortezomib sensitizes SW620 cells to TRAIL-induced apoptosis by downregulating XIAP Inhibition of the mitochondrial amplification loop however cannot explain the lack of complete maturation of caspase-3 in SW620 cells (Figure 1c ). The p20 cleavage fragment detected in this blot is due to the activity of caspase-8. The last step, which is an autocatalytic process yielding the p17 mature form, did not occur. Such an inhibition is observed in cells expressing IAPs. Among IAPs, X-linked inhibitor of apoptosis (XIAP) is the most potent caspase inhibitor (Deveraux and Reed, 1999 ). We therefore compared the level of expression of XIAP in SW480 and 620 cells as well as that of another IAP, survivin. As shown in Figure 4a , survivin is expressed similarly in both cell types, whereas XIAP is found exclusively in SW620 cells and this expression is unchanged by TRAIL stimulation.
As an attempt to inhibit XIAP expression, we used the proteasome inhibitor bortezomib that has been shown to modulate XIAP at the post-translational level in a nuclear factor (NF)-kB-independent manner (Kashkar et al., 2007) . Indeed, bortezomib inhibited XIAP expression in SW620 cells after 6 h of incubation ( Figure 4b ). XIAP can be cleaved by caspase-3 (Leverkus et al., 2003) but this is not the case as we did not detect the p29 cleavage fragment and bortezomib did not activate caspase-3 in SW620 cells (Figure 4b ). Bortezomib induces caspase-3 cleavage in SW480 cells at later times (that is 12 or 24 h) probably due to toxicity of this reagent after lengthy incubations in this cell line (Figure 4b ). Most interestingly, bortezomib treatment was sufficient to sensitize SW620 cells to TRAIL-induced apoptosis as shown in Figure 4c . Bortezomib-induced sensitization of SW620 cells to TRAIL-mediated apoptosis activated cleavage of caspase-8, -9 and -3 and in particular complete maturation of caspase-3 to the p17 form ( Figure 4d ). Bid was also more efficiently cleaved in SW620 cells treated with TRAIL in the presence of bortezomib (Figure 4d compared to Figure 1e ) as expected given the increased maturation of caspase-8. XIAP protein levels have been shown to correlate with NF-kB activation in SW620 cells (Huerta et al., 2007) and bortezomib is known to suppress inhibitor of nuclear factor-kB degradation in the proteasome and thus to abrogate NF-kB activation. We therefore investigated whether bortezomib could modify NF-kB activation in TRAIL-treated cells by monitoring the Sensitization of SW620 cells to TRAIL-induced apoptosis by bortezomib does not lead to mitochondrial permeabilization We then investigated whether the increased caspase-8 activation and Bid cleavage led to an inhibition of the mitochondrial block in SW620 cells. As shown in Figure 5 , cytochrome c and SMAC/Diablo translocated to the cytosol of SW480 cells during the course of TRAIL treatment at an equivalent level whether or not bortezomib was present. In contrast, neither molecule escaped from the mitochondria in SW620 cells even when bortezomib was added. These results show that downregulation of XIAP leads to caspase maturation and apoptosis in TRAIL-treated SW620 cells in a mitochondria-independent manner. In this case, removal of XIAP allows for complete caspase-3 maturation through an autocatalytic process. Caspase-3 then cleaves caspase-9 at an alternative site leading to the generation of the p37 fragment seen in the western blot ( Figure 4d ; Zou et al., 2003) . Autoprocessing of caspase-9 then generates the p35 fragment. Active caspase-3 also leads to increased caspase-8 maturation and this event is known to occur by caspase-6 (Sohn et al., 2005) . Thus, a sort of amplification loop is created with no participation of mitochondria.
XIAP downregulation is sufficient to sensitize SW620 cells to TRAIL-induced apoptosis
Because bortezomib can have other consequences in addition to XIAP downregulation, we inhibited XIAP expression specifically with the use of small-interfering RNA (siRNA). This treatment efficiently abolished XIAP expression ( Figure 6a ) and was sufficient to 
Discussion
In this study, we show that during the progression of a colon carcinoma from the primary tumour (SW480) to a lymph node metastasis (SW620), the tumour cells acquired a TRAIL-resistant phenotype. This resistance was operational at two levels: a mitochondrial block rendering the cells unable to activate Bax despite the generation of tBid by caspase-8 and a cytosolic block of caspase-3 maturation due to XIAP expression. Upon ligand binding, the DISC formed equally well in both cell lines and triggered activation of caspase-8 similarly. Following caspase-8 activation, Bid was efficiently cleaved in these cells but whereas this led to activation of caspase-9 in SW480 cells as expected when mitochondria are disrupted, this was not the case in SW620 cells. Likewise, Bax and Bak were activated in TRAIL-treated SW480 cells but not in SW620 cells. Prevention of mitochondrial permeabilization is generally due to antiapoptotic members of the Bcl-2 family and in particular Mcl-1 has been implicated in the protection against TRAIL-induced apoptosis (Henson et al., 2003; Taniai et al., 2004; Han et al., 2006) . We found that the level of Bcl-2, Bcl-xL as well as Mcl-1 were identical in the SW480 and 620 cell lines. Thus, the mitochondrial resistance to tBid in SW620 cells cannot be explained by increased expression of antiapoptotic Bcl-2 family members.
To promote the release of apoptogenic factors in concert with Bax and Bak proteins, tBid must translocate to the mitochondria (Luo et al., 1998; Wei et al., 2001 ). Therefore, we tested whether tBid could be impaired in its ability to associate with the mitochondria in SW620 cells by generating stable clones expressing tBid-GFP. Of note is the fact that we were unable to obtain such clones in SW480 cells, probably because tBid overexpression is sufficient to kill these cells. In contrast, clones were readily obtained for SW620 cells. The results showed that tBid-GFP did localize to the mitochondria. However, this did not lead to mitochondrial disruption. Although the clones remained resistant to TRAIL, we could induce their apoptotic death with high doses of staurosporine. This allowed us to determine that Bax was functional in the clones and thus that their resistance to tBid could not be explained by impairment of Bax during the clonal selection. The BH3-only protein implicated in staurosporine-induced apoptosis has not been clearly defined but a role for Puma has been suggested (Villunger et al., 2003) . It thus appears that the resistance of SW620 cells would not apply to all BH3-only molecules.
So far, we have been unable to identify the mechanism of resistance of SW620 cells to mitochondrial tBid. We know that this resistance is not due to a defect in tBid as the mitochondria of SW620 cells can sustain exogenous transfected tBid as well as endogenous tBid. A problem with the overall ability of Bax to be activated has also been ruled out. Multiple reports indicate that the mitochondrion-specific cardiolipin is important in the proapoptotic function of tBid (Lutter et al., 2000; Kim et al., 2004; Liu et al., 2004; Gonzalvez et al., 2005a, b; Tyurin et al., 2007) . Therefore, a defect in SW620 cells mitochondrial cardiolipin cannot be excluded. However, in a recent study, RNA interference knockdown of cardiolipin synthase was used to decrease the content of cardiolipin in mitochondria. It was found that under Fas triggering, cell death was accelerated by the reduction of cardiolipin level with more efficient release of cytochrome c and no change in the association of tBid with mitochondria (Choi et al., 2007) . These results cast doubt on the role of cardiolipin in mitochondrial permeabilization. The possibility remains however that other types of molecules are present in the outer mitochondrial membrane that are important for this process. Indeed, it has been reported that tBid is necessary but insufficient for Bax oligomerization and that an additional mitochondrial protein is required (Roucou et al., 2002) . This protein remains unknown but a defect at this level could explain the resistance of SW620 cells to tBid. In a recent report, it was shown that self-assembly of the mitochondrial dynamin Drp1 is necessary for Bid-activated Bax/Bak-dependent mitochondrial membrane permeabilization (Cassidy-Stone et al., 2008) . Alterations of this post-translational modification of Drp1 could impair tBid-induced Bax activation in SW620 cells. Alternatively, it has also been shown that there is an inefficient tBid-induced Bax oligomerization in cells with high mitochondrial cholesterol content, as is often the case in tumour cells (Lucken-Ardjomande et al., 2008) . In an interesting report, it has been shown that combination of C 6 -ceramide with TRAIL can overcome the resistance of SW620 cells to TRAIL-induced apoptosis (VoelkelJohnson et al., 2005) . Whether C 6 -ceramide could unmask the Bax activation blocking signal remains to be determined. ABT-737 acts by binding to and neutralizing Bcl-2, Bcl-xL and Bcl-w (Oltersdorf et al., 2005) whereas tBid is also able to directly activate Bax and Bak by causing an allosteric change (Kim et al., 2006) . The mechanism of resistance of SW620 cells to ABT-737 is thus likely to be different from that to tBid. Sensitivity to ABT-737 has been found to closely correlate with abundance of Bcl-2:Bim complexes (Deng et al., 2007) . This is consistent with a model in which Bcl-2 sequesters BH3 activators from activating Bax or Bak, resulting in a cell 'primed for death', which is dependent upon Bcl-2 function (Certo et al., 2006) . Our results would signify that SW480 cells are 'primed for death' whereas SW620 cells are not. This notion is coherent with our observation that ABT-737 increases TRAIL-induced apoptotic death in SW480 cells but not in SW620 cells. This ability of ABT-737 to potentiate TRAIL-mediated apoptotic signalling has been ascribed to the release of Bim from Bcl-2 (or Bcl-xL) by this compound (Huang and Sinicrope, 2008) . Of note is the fact that we did not find any difference in Bim expression between the two cell lines (not shown) but it would be interesting to investigate whether this BH3 activator is tethered to Bcl-2 or -xL only in SW480 cells.
In the face of this mitochondrial block, it appeared that in SW620 cells caspase-8 was very efficient in cleaving caspase-3 to generate the p20 fragment. However, further autocatalytic maturation of caspase-3 did not occur. We could determine that this was due to a high level of expression of XIAP in SW620 cells whereas this protein is not expressed in SW480 cells. Downregulation of XIAP with siRNA or bortezomib was sufficient to sensitize SW620 cells to TRAILinduced apoptosis. This was accompanied by full maturation of caspase-3 to the p17 fragment, cleavage of caspase-9 and increased cleavage of caspase-8 and Bid. Most interestingly, this increased cleavage of Bid was unable to disrupt the mitochondrial block as shown by the lack of release of cytochrome c and SMAC/ Diablo in SW620 cells even when XIAP was downregulated. Thus, in the face of an acquired inability to disrupt the mitochondria, the cells have converted during tumour progression from a type II (SW480) to a type I apoptotic pathway (SW620). Mere blocking of the mitochondrial step is insufficient for a type II cell to acquire a type I phenotype as we could show that Bcl-2 overexpression in SW480 cells totally protected these cells from TRAIL-mediated apoptosis and did not induce direct cleavage of caspase-3 by -8. Thus, the conversion of SW620 cells to a type I phenotype occurred during the progression to metastatic disease. Expression of XIAP leads to the protection of metastatic cells from TRAIL-induced type I apoptosis.
Sensitization of tumour cells to TRAIL-induced apoptosis by bortezomib has been ascribed to enhanced surface expression of TRAIL receptors (Johnson et al., 2003; Liu et al., 2007; Voortman et al., 2007) , enhanced release of SMAC/Diablo (Johnson et al., 2003; Leverkus et al., 2003; Nagy et al., 2006) , reduction of c-FLIP levels (Sayers et al., 2003; Koschny et al., 2007a) or Bik accumulation (Nikrad et al., 2005; Zhu et al., 2005) . We did find an increased expression of DR4 and 5 in SW620 cells and of DR5 in SW480 cells under the influence of bortezomib (not shown). Inasmuch as the increase of DR5 in SW480 cells did not further sensitize these cells to TRAIL-induced apoptosis, we do not think that the increase in receptor expression contributed to the sensitization of SW620 cells. Indeed, the contribution of receptor upregulation to TRAIL sensitization is a matter of debate (Kyritsis et al., 2007; Koschny et al., 2007a) . We showed that bortezomib did not lead to the release of SMAC/Diablo from the mitochondria in SW620 cells and that FLIP is not expressed in these cells. We did not investigate Bik expression. In any case, XIAP downregulation appears crucial for bortezomibinduced TRAIL sensitization in SW620 cells as extinction of XIAP expression with specific siRNA was sufficient to restore apoptotic signalling in these cells.
In conclusion, we show that during metastasis formation, the SW620 cells have acquired resistance to TRAIL-mediated apoptosis through two main checkpoints (a) a block at the mitochondria rendering the cells Acquired resistance to TRAIL in metastatic colon cancer O Ndozangue-Touriguine et al resistant to tBid-induced Bax activation and (b) a conversion from types II to I apoptotic pathway and an upregulation of XIAP to inhibit this type I apoptotic signalling. Even if our observations are restricted to a tumour, it is interesting that in the course of tumour progression two major modifications occurred to ensure inhibition of TRAIL-induced apoptosis. Acquisition of such alterations would not only inhibit cell-mediated cytotoxicity induced by TRAIL but also by granzyme-B. Indeed, granzyme-B transduces death signals either by cleaving Bid to generate gtBid and activate the mitochondrial pathway or by directly cleaving procaspase-3 such as caspase-8. It has been shown that coexisting defects in mitochondrial death signalling together with expression of XIAP induce resistance to immunological cytotoxicity and adoptive immunotherapy (Ravi et al., 2006) . Thus, these properties would confer the ability to escape immune surveillance on metastatic cells.
Materials and methods
Additional materials and methods can be found in Supplementary information.
DISC immunoprecipitation
The TRAIL-induced DISC was immunoprecipitated using 10 8 cells treated with 5 mg of Flag-tagged TRAIL cross-linked with 10 mg of anti-Flag M2 for 15, 30 or 60 min at 37 1C in 1 ml medium. Cells were harvested, washed twice with ice-cold phosphate-buffered saline (PBS) and then lysed on ice in 1% NP-40 lysis buffer. After clarification, lysates were immunoprecipitated overnight at 4 1C with protein G-Sepharose beads (Sigma-Aldrich, St-Quentin-Fallavier, France). Beads were then washed three times in lysis buffer, boiled in sample buffer and proteins separated by SDSpolyacrylamide gel electrophoresis. Blots were probed with appropriate antibodies and proteins visualized by enhanced chemiluminescence.
Subcellular fractionation
Cytosolic and mitochondrial fractions were prepared according to (Ceballos-Cancino et al., 2007) with some modifications.
Briefly, 6 Â 10 6 cells were harvested and washed twice in icecold PBS. The harvested pellets were resuspended in 200 ml of cytosolic lysis buffer (250 mM sucrose, 70 mM KCl, 137 mM NaCl, 4.3 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4 (pH 7.2), 70 mg/ml digitonin, 100 mM phenylmethylsulphonyl fluoride (PMSF), protease inhibitor cocktail) for 30 min on ice. Cells were centrifuged for 5 min at 1000 g. The resulting supernatant was collected as the cytosolic fraction and the pellet was resuspended in 200 ml of mitochondrial lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.2% (v/v) Triton X-100, 0,3% NP-40, PMSF, protease inhibitor cocktail) for 5 min on ice. The suspension obtained was centrifuged at 10 000 g for 10 min and the resulting supernatant was kept as the mitochondrial fraction.
Small-interfering RNA-mediated silencing of XIAP Cells were seeded in six-well plates to reach 50-60% confluency and were then transfected with specific or nonspecific siRNA, which were left for 48 h. Each siRNA was used at 100 nM. The transfection was accomplished with 30 ml INTERFERin (Polyplus transfection, Ozyme, St-Quentin-en Yvelines, France). This siRNA transfection reagent was added to siRNA duplex in 100 ml of Opti-MEM (Gibco, Illkirch, France). At 48 h after transfection cells were treated with TRAIL (25 ng/ml) for 24 and 48 h.
The siRNA-targeting XIAP mRNA was pre-designed and validated corresponding to the following sequences: sense 5 0 -GGAGAUACCGUGCGGUGCUdTdT-3 0 and antisense 5 0 -AGCACCGCACGGUAUCUCCdTdT-3 0 . The negative control siRNA used was designed by QIAGEN (Courtaboeuf, France) with the following sequences: sense 5 0 -UUCUCCGAA CGUGUCACGUdTdT-3 0 and antisense 5 0 -ACGUGACACG UUCGGAGAAdTdT-3 0 .
tBid-GFP plasmid construct
A plasmid expressing the fusion protein full-length Bid (corresponding to 1-195 amino acid)/enhanced green fluorescent protein (EGFP) was kindly provided by A Lopez-Rivas (Ortiz-Ferron et al., 2006) . The plasmid expressing the fusion protein-truncated Bid (corresponding to 61-195 amino acid)/ EGFP was obtained by modifying the above construct. The FL-Bid-GFP fragment was excised from pEF4/Myc-His B vector with KpnI and BamHI and the human-truncated Bid cDNA was obtained by PCR using the following primers, forward 5 0 -GGGGTACCATGGGCAACCGCAGCAGCCA CTCC-3 0 and reverse 5 0 -GGCGATGGATCCGTCCATCCC ATT-3 0 . The PCR product was cloned directly into the same vector (pEF4/Myc-His B).
Stable transfection and tBid-GFP clone generation
Stable cell lines were made by transfecting SW480 and 620 cells with 5 mg of DNA along with 10 ml of JetPEI. (Polyplus transfection, Ozyme). At 2 days after transfection, cells were split into four 75 cm 2 flasks and 200 mg/ml of selective reagent, Zeocin (Invivogen) was added. Several clones from each individual plate were selected and tested for expression of fusion protein tBid-GFP by fluorescence microscopy.
